Branded Generics Market Size, Share & Trends Report

Branded Generics Market Size, Share & Trends Analysis By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive), By Application, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-4-68039-943-5
  • Number of Pages: 155
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Research Methodology

A three-pronged approach was followed for deducing the branded generics market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for branded generics market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of branded generics market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Branded Generics Market Categorization:

The branded generics market was categorized into five segments, namely drug class (Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering Drugs, Anti-depressants, Anti-psychotics, Anti-epileptics), application (Oncology, Cardiovascular Diseases, Neurological Diseases, Gastrointestinal Diseases, Dermatological Diseases, Acute And Chronic Pain), route of administration (Topical, Oral, Parenteral), distribution channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The branded generics market was segmented into drug class, application, route of administration, distribution channel, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The branded generics market was analyzed at a regional level. The global was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; Germany; the UK.; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand, Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Branded generics market companies & financials:

The branded generics market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • Teva Pharmaceutical Industries Ltd. is an Israel-based pharmaceutical company and has a presence in around 100 countries. It is a leading manufacturer of generic drugs and also specializes in producing proprietary pharmaceuticals, contraceptive drugs & Active Pharmaceutical Ingredients (APIs) for healthcare. The company is primarily focused on specialty medicines, OTC products, generic drugs, APIs, and branded molecules. It is a global leader in generics & specialty medicines and offers its products in nearly every therapeutic area. Teva’s core therapeutic areas are central nervous system disorders, respiratory illnesses, oncology, and women’s health. It is engaged in R&D in the fields of generic drugs, new chemical entities, personalized medicine, biologics, and research technology. The company’s pipeline consists of drugs for the central nervous system, pain, and respiratory therapeutic areas.

  • Lupin is an Indian pharmaceutical company involved in the manufacturing and marketing of branded, generic formulations, biosimilars, and APIs. The company offers its products majorly in Asia Pacific, MEA, and Latin America. Lupin offers products for a wide range of therapy segments such as cardiology, CNS, anti-diabetes, anti-TB, anti-asthma, gynecology, anti-infective, gastrointestinal, and others. The company holds a leading position in the anti-TB and Cephalosporin segments. Lupin is focused on strengthening its pipeline in women’s health, neurology, cardiac, diabetes, respiratory, ophthalmic, and dermatology in different regions. The company along with its subsidiaries has manufacturing locations across India, Japan, the U.S., Mexico, and Brazil. Lupin is significantly investing in complex generic platform technologies to advance its generic R&D pipeline.           

  • Sanofi is a multinational pharmaceutical company engaged in the research, production, and marketing of pharmaceutical products. The company operates through pharmaceuticals, consumer health, and vaccines business segments. To improve access to healthcare, Sanofi provides solutions in human vaccines, rare diseases, oncology, infectious diseases, and consumer healthcare. The pharmaceutical segment comprises specialty care, diabetes & cardiovascular, established prescription products, and generics. The company’s specialty care unit is its highest revenue-generating segment. The vaccine segment consists of the commercial operations of Sanofi Pasteur. The company has 73 production sites and 20 R&D sites located in around 100 countries.

  • Sun Pharmaceutical Industries, Ltd. is an India-based pharmaceutical company that operates through business segments, including therapy areas such as cardiology, gastroenterology, diabetology, dermatology, and neuropsychiatry. It is the one of largest specialty generic pharmaceuticals companies and is the leading company in India. It provides quality products in more than 100 countries. The global presence of the company is supported by more than 40 manufacturing plants and R&D centers worldwide. The company is involved in the research and manufacturing of generics, branded products, specialty products, OTC products, and APIs. The range of products includes tablets, capsules, ointments, injectables, liquids, and more. In addition, the company has over 40 manufacturing units located in North America, Europe, Asia Pacific, and MEA.   

  • Dr. Reddy’s Laboratories Ltd. is a pharmaceutical company headquartered in India. Their business portfolio offers generics, OTC products, APIs, custom pharmaceutical services, biologics, and differentiated formulations. The company offers more than 200 high-quality generic forms of innovative medicines in over 80 countries. Generic formulation includes tablets, capsules, injectables, and topical creams. The company majorly focuses on oncology, gastroenterology, cardiovascular, anti-diabetics, dermatology, and pain management. Its generic formulation business is present in the U.S., Europe, Korea, Japan, Latin America, and other emerging markets.

  • Endo International plc is a global specialty and generics pharmaceutical company. In the pharmaceutical sector, the company has two subsidiaries: Endo Pharmaceuticals and Par Pharmaceutical. Endo Pharmaceuticals segment offers branded prescription drugs and involves the development and manufacturing of prescription drugs. The key focus areas of the branded drug segment are insomnia, urology, dermatology, and pain management, among others. In 2015, the company acquired a broad portfolio of branded and generic established products focused on pain, anti-infectives, and other specialty therapeutic areas from Aspen Holdings. Moreover, it has acquired U.S.-based Par Pharmaceutical, which is involved in the manufacturing and marketing of generic pharmaceutical products. Par Pharmaceutical specializes in modified-released non-oral dosage forms such as injectables, nasal sprays, patches, and other alternative delivery platforms.     

  • GlaxoSmithKline plc (GSK) is engaged in three businesses globally: research, development, and manufacturing of innovative pharmaceutical medicines, vaccines, & consumer healthcare products. The company aims to develop high-quality and differentiated products. The pharmaceutical business consists of a broad portfolio of commercially available innovative and established medicines for respiratory diseases and HIV/AIDS. The company’s R&D focuses mainly on the immune system and application of genetics & advanced technologies. It majorly invests in scientific and technical excellence to develop and launch pipeline products that meet the needs of patients, consumers, and payers. The company developed several vaccines and delivered around 2 million vaccine doses per day to people living in 160 countries. It has been in the respiratory diseases segment for 40 years and has broadened & strengthened its portfolio by adding new medicines containing ICS, LAMA, and LABA.

  • Pfizer, Inc. is a multinational U.S. pharmaceutical company headquartered in New York. It is involved in the discovery, development, and manufacturing of pharmaceutical products. Pfizer has a portfolio of vaccines and medicines. The company operates in two business segments: Essential Health (EH) and Innovative Health (IH). The EH segment includes branded generics, biosimilars, infusion systems, generic sterile injectable products, and legacy brands. The IH segment works toward the commercialization and development of medicines and vaccines. This segment operates in various therapeutic segments: internal medicine, immunology, consumer healthcare, oncology, inflammation, rare diseases, and vaccines. It has 42 manufacturing facilities and operates in over 125 countries.

  • Viatris, Inc. was founded after a merger between Mylan and Pfizer, Inc. The company focuses on increasing access to inexpensive, high-quality medications for patients around the world by combining the resources of its two parent companies, including its global workforce of nearly 38,000 employees. Its portfolio includes best-in-class branded generics and key global brands, generics including branded & complicated generics, biosimilars, and OTC products in a variety of therapeutic areas. Its reach includes North America, Europe, Asia Pacific, and emerging markets.

  • Apotex, Inc. is a Canadian pharmaceutical firm that manufactures high-quality, cost-effective medicines (generic and novel pharmaceuticals) for patients globally. The Apotex Group of Companies comprises Apotex Generics, Apotex Active Pharmaceutical Ingredients, and Apobiologix. The company operates in over 45 countries and has a presence in over 115 countries and territories, with a strong presence in the U.S., Mexico, and India.

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

Branded Generics Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Branded Generics Market Report Assumptions:

  • The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

  • Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

  • Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.

What questions do you have? Get quick response from our industry experts. Request a Free Consultation



This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon